There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Warfarin sodium is widely used and causes bleeding; a review might suggest the need
for regulatory action by the US Food and Drug Administration (FDA).
[1
]
Division of Drug Risk Evaluation, Food and Drug Administration, White Oak, Bldg 22,
Room 3424, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA. diane.wysowski@fda.hhs.gov